Ipamorelin benefits: claims against evidence

No human study has measured muscle mass or strength after ipamorelin. The closest animal measurement is a three-month rat study in which maximum tetanic tension of the calf muscles was higher in animals given a glucocorticoid plus ipamorelin than in animals given the glucocorticoid alone [Andersen 2001]. That is a counteraction of a drug-induced deficit in rats, measured against drug-treated controls, not a gain in healthy animals and not a human result.

In GH-deficient and GH-intact mice, ipamorelin increased fat pad weights relative to body weight and increased relative body fat measured by DEXA, along with serum leptin and food intake. Growth hormone itself decreased relative fat mass in the same experiment. The authors concluded that secretagogues increase body fat through GH-independent mechanisms that may include increased feeding [Lall 2001]. No human study has measured body composition after ipamorelin.

No human IGF-1 measurement after ipamorelin is indexed. In rats given ipamorelin for 15 days, bone growth rate rose dose-dependently while total IGF-1 and IGF binding proteins were unchanged [Johansen 1999]. In diabetic mice, growth hormone rose to more than double the non-diabetic level while IGF-1 did not rise at all [Johansen 2003]. IGF-1 did rise in glucocorticoid-treated rats given repeated dosing over 10 days [Aagaard 2009]. The step is conditional, not automatic.

No indexed study measures athletic or injury recovery in humans or animals. The word “recovery” in the ipamorelin literature refers to recovery of gastrointestinal function after bowel surgery — a different thing entirely — and in the randomised trial of that endpoint the result was not significant [Beck 2014]. A 2026 scoping review covering ipamorelin among six peptides for musculoskeletal recovery notes the absence of efficacy and safety data for many of them [Tewari 2026].

No indexed study measured sleep, in any species. There is nothing to report for or against this claim.

No indexed study measured any ageing endpoint. Reviews that discuss peptides in gerontology mention ipamorelin within a broad compound class, but they contain no ipamorelin-specific outcome data, and a 2020 review of secretagogues in hypogonadal men states in its own conclusions that clinical efficacy data largely remain lacking [Sinha 2020].

This one needs care. In rats given ipamorelin for 12 weeks, total tibial and vertebral bone mineral content increased — but content corrected for body weight was unaffected, and total and vertebral areal bone mineral density were unchanged. Peripheral quantitative computed tomography showed the cortical increase came from greater cross-sectional bone area while cortical volumetric density was unchanged [Svensson 2000]. In other words the bones got bigger, not denser. A separate study measured an increased longitudinal growth rate in rats [Johansen 1999]. No human bone measurement exists.

This is the one claim with direct human support. In 40 healthy men, each intravenous infusion produced a single pulse of growth hormone peaking at 0.67 hours and declining to negligible concentrations[Gobburu 1999]. It is well established in rat pituitary cells, rats and swine too[Raun 1998]. What the human study did not measure is any consequence of that pulse: no IGF-1, no body composition, no clinical outcome.

This is the only indication ever taken into controlled human trials, and it is the claim with the most rigorous test behind it. Rodent models showed accelerated gastric emptying and faster time to first bowel movement [Venkova 2009] [Greenwood-Van 2012]. In the randomised placebo-controlled trial in 117 patients, median time to first tolerated meal was 25.3 hours against 32.6 hours for placebo, which did not reach significance (P = 0.15), and the authors reported no significant differences in the key and secondary efficacy analyses [Beck 2014]. A larger trial of 320 patients has never reported[NCT01280344].

In rats with acetic-acid-induced visceral hypersensitivity, ipamorelin reduced the visceromotor response to colorectal distension and somatic allodynia, and a ghrelin receptor antagonist blocked both effects[N 2020]. These are behavioural pain surrogates in rats. No human study has measured pain.